Tumor Mutation Burden and Efficacy of Nivolumab Monotherapy and in Combination With Ipilimumab in Small Cell Lung Cancer

Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutation burden (TMB) on efficacy of nivolumab monotherapy or combi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Hellmann, Matthew D., Callahan, Margaret K., Awad, Mark M., Calvo, Emiliano, Ascierto, Paolo A., Atmaca, Akin, Rizvi, Naiyer A., Hirsch, Fred R., Selvaggi, Giovanni, Szustakowski, Joseph D., Sasson, Ariella, Golhar, Ryan, Vitazka, Patrik, Chang, Han, Geese, William J., Antonia, Scott J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6750707/
https://ncbi.nlm.nih.gov/pubmed/29731394
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2018.04.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados